Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Efzofitimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Efzofitimod overview
efzofitimod (ATYR-1923) is under development for the treatment of rare pulmonary diseases with an immune component (RPIC) including interstitial lung diseases such as chronic hypersensitivity pneumonitis and connective tissue diseases (CTD-ILD), pulmonary sarcoidosis, systemic sclerosis related interstitial lung disease (SSc-ILD), rheumatoid arthritis and coronavirus disease 2019 (COVID-19) with severe pneumonia. It is administered by intravenous route. The drug candidate targets neuropilin-2. It is being developed based on tRNA synthetase platform. The drug candidate constitutes an immunoglobin Fc fused with the immuno-modulatory domain (iMod domain) of histidine aminoacyl tRNA synthetase (HARS).
It was under development for acute lung injury.
ATyr Pharma overview
aTyr Pharma is a clinical-stage biotechnology company. The company’s pipeline products include efzofitimod for the treatment of pulmonary sarcoidosis, scleroderma related ILD (SSc-ILD), connective tissue disease-ILD ( CTD-ILD); chronic hypersensitivity pneumonitis (CHP); ATYR0101 treats fibrosis; ATYR0750 targets liver disorders. The company collaborates with research institutions for its research and development activities. It also concentrates on research and development of the extracellular functionality of tRNA synthetases. The company utilizes tRNA synthetase biology platform to develop drugs. aTyr Pharma is headquartered in San Diego, California, the US.
For a complete picture of Efzofitimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
